PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.

Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.

Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.

Mirati raises $300m as its chief exec departs. What’s not to like?

Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.